Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The impact of human CES1 genetic variation on enzyme activity assessed by ritalinic acid/methylphenidate ratios

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Acetaminophen toxicity induces mitochondrial complex I inhibition in human liver tissue

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pharmacokinetics of Ferric bepectate - a new intravenous iron drug for treating iron deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Short-course vs long-course antibiotic treatment for community-acquired pneumonia: A literature review

    Research output: Contribution to journalReviewResearchpeer-review

  1. Midazolam Pharmacokinetics in Obese and Non-obese Children and Adolescents

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pharmacogenetics of antiemetics for chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis

    Research output: Contribution to journalReviewResearchpeer-review

  3. A rare missense variant in APC interrupts splicing and causes AFAP in two Danish families

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Restriction of non-opioid analgesics sold over-the-counter in Denmark: A national study of impact on poisonings

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The present clinical trial investigated the impact of selected SNPs in CES1 on the metabolic activity of the enzyme. For this purpose, we used methylphenidate (MPH) as a pharmacological probe and the d-RA/d-MPH (metabolite/parent drug) ratios as a measure of enzymatic activity. This metabolic ratio (MR) was validated against the AUC ratios (AUC d -RA/AUC d -MPH). CES1 SNPs from 120 volunteers were identified, and 12 SNPs fulfilling predefined inclusion criteria were analysed separately, comparing the effect of each genotype on the metabolic ratios. The SNP criteria were as follows: presence of Hardy-Weinberg equilibrium, a minor allele frequency ≥ 0.01 and a clearly interpretable sequencing result in at least 30% of the individuals. Each participant ingested 10 mg of racemic methylphenidate, and blood samples were drawn prior to and 3 hours after drug administration. The SNP analysis confirmed the considerable impact of rs71647871 (G143E) in exon 4 on drug metabolism. In addition, three volunteers with markedly lower median MR, indicating decreased CES1 activity, harboured the same combination of three SNPs in intron 5. The median MR for these SNPs was 8.2 for the minor allele compared to 16.4 for the major alleles (P = 0.04). Hence, one of these or the combination of these SNPs could be of clinical significance considering that the median MR of the G143E group was 5.4. The precise genetic relationship of this finding is currently unknown, as is the clinical significance.

Original languageEnglish
JournalBasic & clinical pharmacology & toxicology
Volume125
Issue number1
Pages (from-to)54-61
Number of pages8
ISSN1742-7843
DOIs
Publication statusPublished - Jul 2019

Bibliographical note

© 2019 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

    Research areas

  • carboxylesterase 1, metabolic ratio, Methylphenidate, pharmacogenetics, pharmacokinetics

ID: 56746152